Express News | Bio-Techne Corp : RBC Raises Target Price to $77 From $70
Here's What Dragged Bio-Techne Corporation (TECH)?
Bio-Techne To Present At 2024 Wells Fargo Healthcare Conference; Webcast At 11:00 AM ET
BofA's Global Contenders and Defenders List
Some Investors May Be Willing To Look Past Bio-Techne's (NASDAQ:TECH) Soft Earnings
Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Baird analyst Catherine Ramsey Schulte maintains $Bio-Techne(TECH.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of 56.0%
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
ScaleReady Announces the Inaugural G-Rex Grant Has Been Awarded to Stanford Medicine Laboratory for Cell and Gene Medicine
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH)
Bio-Techne | 10-K: FY2024 Annual Report
Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $83
Scotiabank analyst Sung Ji Nam maintains $Bio-Techne(TECH.US)$ with a buy rating, and maintains the target price at $83.According to TipRanks data, the analyst has a success rate of 49.2% and a
Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)
Bio-Techne To Go Ex-Dividend On August 19th, 2024 With 0.08 USD Dividend Per Share
August 15th (Eastern Time) - $Bio-Techne(TECH.US)$ is trading ex-dividend on August 19th, 2024.Shareholders of record on August 19th, 2024 will receive 0.08 USD dividend per share on August 30th, 2024
Bio-Techne Price Target Maintained With a $95.00/Share by Benchmark
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95
Benchmark Co. analyst Robert Wasserman maintains $Bio-Techne(TECH.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 37.8%
Benchmark Co. Remains a Buy on Bio-Techne (TECH)
Bio-techne Insider Sold Shares Worth $1,153,664, According to a Recent SEC Filing